NEW YORK (GenomeWeb) – Sophia Genetics announced five partnerships with UK healthcare institutions for use of the company's data analysis platform to clinically interpret genetic information.
The deals are with Oxford University Hospital, Newcastle Medical Genetics, Aberdeen Medical Genetics, Liverpool Women's NHS Foundation Trust, and New Gene. They will use Sophia's Data Driven Medicine Platform, which employs machine learning and algorithms to analyze patients' genomic samples.
Christine Bell, a healthcare scientist and principal consultant for Aberdeen Medical Genetics, said in a statement that Sophia's technology has allowed it to investigate and validate its gene panel "more quickly and with greater confidence than we could have done on our own, speeding up the process of introducing the new NGS test to our routine service."
In April, Lausanne, Switzerland-based Sophia reached deals with University Hospitalin Düsseldorf, Germany and University Hospital Cologne, Germany to use the company's platform to run and validate an NGS-based test for hereditary breast and ovarian cancer.